Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

Onno C P van Schayck, John Haughney, Michel Aubier, Olof Selroos, Tommy Ekström, Juliette Ostinelli, Roland Buhl

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.

METHODS: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (®) Turbuhaler(®))(h) maintenance and reliever therapy (Symbicort SMART(®)) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a smoking history <10 pack-years if older), who were compared with a propensity-matched group of non-smokers. At baseline, smokers had lower post-bronchodilator peak expiratory flow, lower peak flow reversibility and used more reliever medication per day. Severe asthma exacerbations were counted and changes in five-item Asthma Control Questionnaire (ACQ-5) scores from baseline calculated.

RESULTS: There were 48 and 47 exacerbations in smokers and non-smokers, respectively. Mean time to first severe exacerbation was not statistically different between the two groups. The mean change in ACQ-5 score was significantly greater in non-smokers. Considering the two treatment options there was a statistically significant prolonged time to first severe exacerbation with 2 × 2 versus 1 × 2 in the smokers, but not in the non-smokers. In smokers, the reductions in ACQ-5 scores, asthma symptoms, use of as-needed medication and awakenings were also all significant in favour of 2 × 2 with similar or greater changes than in smokers treated with 1 × 2.

CONCLUSION: Asthmatic patients with a limited smoking history benefit from treatment with budesonide/formoterol maintenance and reliever therapy with dosing 2 × 2 being superior to 1 × 2.

Original languageEnglish
Pages (from-to)189-196
Number of pages8
JournalRespiratory Medicine
Volume106
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Budesonide
Maintenance
Asthma
Smoking
Adrenal Cortex Hormones
Therapeutics
History
Bronchodilator Agents
Formoterol Fumarate
Research Design

Keywords

  • administration, inhalation
  • adult
  • anti-asthmatic agents
  • asthma
  • bronchodilator agents
  • budesonide
  • disease progression
  • dose-response relationship, drug
  • drug administration schedule
  • drug therapy, combination
  • ethanolamines
  • female
  • formoterol fumarate
  • humans
  • male
  • peak expiratory flow rate
  • smoking
  • surveys and questionnaires
  • treatment outcome

Cite this

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. / van Schayck, Onno C P; Haughney, John; Aubier, Michel; Selroos, Olof; Ekström, Tommy; Ostinelli, Juliette; Buhl, Roland.

In: Respiratory Medicine, Vol. 106, No. 2, 02.2012, p. 189-196.

Research output: Contribution to journalArticle

van Schayck, Onno C P ; Haughney, John ; Aubier, Michel ; Selroos, Olof ; Ekström, Tommy ; Ostinelli, Juliette ; Buhl, Roland. / Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. In: Respiratory Medicine. 2012 ; Vol. 106, No. 2. pp. 189-196.
@article{feda20c4f7f14051839b0f985b94e6f3,
title = "Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy?: Results of an open label study",
abstract = "BACKGROUND: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.METHODS: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ({\circledR}) Turbuhaler({\circledR}))(h) maintenance and reliever therapy (Symbicort SMART({\circledR})) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β(2)-agonists. The 8424 randomised patients included 886 smokers (11{\%}; aged <40 years or with a smoking history <10 pack-years if older), who were compared with a propensity-matched group of non-smokers. At baseline, smokers had lower post-bronchodilator peak expiratory flow, lower peak flow reversibility and used more reliever medication per day. Severe asthma exacerbations were counted and changes in five-item Asthma Control Questionnaire (ACQ-5) scores from baseline calculated.RESULTS: There were 48 and 47 exacerbations in smokers and non-smokers, respectively. Mean time to first severe exacerbation was not statistically different between the two groups. The mean change in ACQ-5 score was significantly greater in non-smokers. Considering the two treatment options there was a statistically significant prolonged time to first severe exacerbation with 2 × 2 versus 1 × 2 in the smokers, but not in the non-smokers. In smokers, the reductions in ACQ-5 scores, asthma symptoms, use of as-needed medication and awakenings were also all significant in favour of 2 × 2 with similar or greater changes than in smokers treated with 1 × 2.CONCLUSION: Asthmatic patients with a limited smoking history benefit from treatment with budesonide/formoterol maintenance and reliever therapy with dosing 2 × 2 being superior to 1 × 2.",
keywords = "administration, inhalation, adult, anti-asthmatic agents, asthma, bronchodilator agents, budesonide, disease progression, dose-response relationship, drug, drug administration schedule, drug therapy, combination, ethanolamines, female, formoterol fumarate, humans, male, peak expiratory flow rate, smoking, surveys and questionnaires, treatment outcome",
author = "{van Schayck}, {Onno C P} and John Haughney and Michel Aubier and Olof Selroos and Tommy Ekstr{\"o}m and Juliette Ostinelli and Roland Buhl",
note = "Crown Copyright {\circledC} 2011. Published by Elsevier Ltd. All rights reserved.",
year = "2012",
month = "2",
doi = "10.1016/j.rmed.2011.10.017",
language = "English",
volume = "106",
pages = "189--196",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy?

T2 - Results of an open label study

AU - van Schayck, Onno C P

AU - Haughney, John

AU - Aubier, Michel

AU - Selroos, Olof

AU - Ekström, Tommy

AU - Ostinelli, Juliette

AU - Buhl, Roland

N1 - Crown Copyright © 2011. Published by Elsevier Ltd. All rights reserved.

PY - 2012/2

Y1 - 2012/2

N2 - BACKGROUND: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.METHODS: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (®) Turbuhaler(®))(h) maintenance and reliever therapy (Symbicort SMART(®)) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a smoking history <10 pack-years if older), who were compared with a propensity-matched group of non-smokers. At baseline, smokers had lower post-bronchodilator peak expiratory flow, lower peak flow reversibility and used more reliever medication per day. Severe asthma exacerbations were counted and changes in five-item Asthma Control Questionnaire (ACQ-5) scores from baseline calculated.RESULTS: There were 48 and 47 exacerbations in smokers and non-smokers, respectively. Mean time to first severe exacerbation was not statistically different between the two groups. The mean change in ACQ-5 score was significantly greater in non-smokers. Considering the two treatment options there was a statistically significant prolonged time to first severe exacerbation with 2 × 2 versus 1 × 2 in the smokers, but not in the non-smokers. In smokers, the reductions in ACQ-5 scores, asthma symptoms, use of as-needed medication and awakenings were also all significant in favour of 2 × 2 with similar or greater changes than in smokers treated with 1 × 2.CONCLUSION: Asthmatic patients with a limited smoking history benefit from treatment with budesonide/formoterol maintenance and reliever therapy with dosing 2 × 2 being superior to 1 × 2.

AB - BACKGROUND: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.METHODS: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (®) Turbuhaler(®))(h) maintenance and reliever therapy (Symbicort SMART(®)) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a smoking history <10 pack-years if older), who were compared with a propensity-matched group of non-smokers. At baseline, smokers had lower post-bronchodilator peak expiratory flow, lower peak flow reversibility and used more reliever medication per day. Severe asthma exacerbations were counted and changes in five-item Asthma Control Questionnaire (ACQ-5) scores from baseline calculated.RESULTS: There were 48 and 47 exacerbations in smokers and non-smokers, respectively. Mean time to first severe exacerbation was not statistically different between the two groups. The mean change in ACQ-5 score was significantly greater in non-smokers. Considering the two treatment options there was a statistically significant prolonged time to first severe exacerbation with 2 × 2 versus 1 × 2 in the smokers, but not in the non-smokers. In smokers, the reductions in ACQ-5 scores, asthma symptoms, use of as-needed medication and awakenings were also all significant in favour of 2 × 2 with similar or greater changes than in smokers treated with 1 × 2.CONCLUSION: Asthmatic patients with a limited smoking history benefit from treatment with budesonide/formoterol maintenance and reliever therapy with dosing 2 × 2 being superior to 1 × 2.

KW - administration, inhalation

KW - adult

KW - anti-asthmatic agents

KW - asthma

KW - bronchodilator agents

KW - budesonide

KW - disease progression

KW - dose-response relationship, drug

KW - drug administration schedule

KW - drug therapy, combination

KW - ethanolamines

KW - female

KW - formoterol fumarate

KW - humans

KW - male

KW - peak expiratory flow rate

KW - smoking

KW - surveys and questionnaires

KW - treatment outcome

U2 - 10.1016/j.rmed.2011.10.017

DO - 10.1016/j.rmed.2011.10.017

M3 - Article

C2 - 22119455

VL - 106

SP - 189

EP - 196

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 2

ER -